MetrioPharm AG Investor Relations News
-
MetrioPharm Investor Relations News QIV 2018
Topics: Retrospect of the year by CEO Dr. Wolfgang Brysch, Events, Blog, Company Calendar
-
MetrioPharm Investor Relations News QIII 2018
Topics: Update on the ongoing Phase-II-study, MetrioPharm in Stockholm, Investor Talks in New York, Herbstkonferenz in Frankfurt, Company Calendar
-
MetrioPharm Investor Relations News QII 2018
Topics: 12th Annual General Meeting, Investor Talks in Munic, Swiss Biotech Day in Basel, MetrioPharm in Boston, SFRRI Meeting in Lisbon, Investor Talks in Dublin, Corporate Calendar
-
MetrioPharm Investor Relations News QI 2018
Topics: Greetings from Dr. Wolfgang Brysch, CEO of MetrioPharm AG, First Patient First Dose, MetrioPharm Blog, J.P. Morgen Healthcare Conference, Swiss Nordic Bio, Investor Talks in Monaco, Corporate Calendar
-
MetrioPharm Investor Relations News QIV 2017
Topics: End-of-the-year Review by CEO Dr. Wolfgang Brysch, Bio-Europe 2017 Berlin, German Equity Forum 2017, Investor Talks with MetrioPharm AG in New York, Company Calendar of MetrioPharm AG in QI 2018
-
MetrioPharm Investor Relations News QIII 2017
Topics: Filing of Phase II Study in Psoriasis Patients, 10th Anniversary of MetrioPharm AG, Extraordinary Annual General Meeting, Corporate Calendar of MetrioPharm AG
-
MetrioPharm Investor Relations News QII 2017
Topics: 11th Annual General Meeting, Letter to MetrioPharm Shareholders, German Biotechnology Days, Swiss Biotech Day, BioEquity Europe, Corporate Calendar of MetrioPharm AG
-
MetrioPharm Investor Relations News QI 2017
Topics: Phase IIa Results, JP Morgan Healthcare conference, BioEurope Spring, Corporate Calendar of MetrioPharm AG
-
Investor Relations News QIV 2016
Topics: End-of-the-year Review, Feedback on the Perception Study, MetrioPharm AG at German Equity Forum 2016, Financial Calender of MetrioPharm AG in QI 2017
-
Investor Relations News QIII 2016
Topics: Financial Calendar of MetrioPharm AG, Capital Increase, Investor Relations Perception Study, Current Status of MP1032’s Phase IIa in Psoriasis, About Us: Clinical Development.